News
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
Gemma Collins says she was shocked by how her face changed after losing two stone on Mounjaro. Experts warn of a side effect ...
7h
Stocktwits on MSNHims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent ExpiresHims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...
Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...
For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results